Home » Stocks » ANTH

Anthera Pharmaceuticals, Inc. (ANTH)

Stock Price: $0.0444 USD 0.0044 (11.00%)
Updated Jul 23, 2021 3:44 PM EDT - Market closed
Market Cap 1.16M
Revenue (ttm) n/a
Net Income (ttm) -24.93M
Shares Out 22.17M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $0.0444
Previous Close $0.0400
Change ($) 0.0044
Change (%) 11.00%
Day's Open 0.0445
Day's Range 0.0444 - 0.0600
Day's Volume 100,165
52-Week Range 0.0100 - 0.1900

News

Hide News

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has assigned Long Term Issue Credit Ratings of “bbb+” to the newly issued senior unsecured notes of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE:ANTH], which to...

4 months ago - Business Wire

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has commented that the Credit Ratings (ratings) of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE: ANTH] and its insurance subsidiaries remain unchanged following...

5 months ago - Business Wire

About ANTH

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license ... [Read more...]

Industry
Biotechnology
IPO Date
Mar 1, 2010
CEO
J. Craig Thompson
Employees
21
Stock Exchange
OTCMKTS
Ticker Symbol
ANTH
Full Company Profile

Financial Performance

Financial Statements